Image

Europe Clinical Trial Imaging Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Published Report
  • Sep 2022
  • Europe
  • 350 Pages
  • No of Tables: 173
  • No of Figures: 44
  • Healthcare
  • Published Report
  • Sep 2022
  • Europe
  • 350 Pages
  • No of Tables: 173
  • No of Figures: 44

Europe Clinical Trial Imaging Market, By Product and Services (Services and Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-ray, Ultrasound, Optical Coherence Tomography and Others), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Hematology and Others), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturers, Academic and Government Research Institutes and Others), Distributor (Direct Sales and Tender Sales) - Industry Trends and Forecast to 2029.

Clinical Trial Imaging Market

Europe Clinical Trial Imaging Market Analysis and Insight

The increasing demand for imaging technology, followed by rise in the prevalence of chronic diseases due to rise in elderly population and strategic initiatives by market players such as product launch, advancement, acquisition and agreements are the factors that are expected to drive the market growth.

Clinical Trial Imaging Market

Clinical Trial Imaging Market

However, improper and unfavourable reimbursement scenarios for imaging devices and lack of well-defined standards in clinical trial imaging instruments are expected to restrain the market growth.

The rising technological progressions in clinical trial imaging for diagnosis and treatment of chronic diseases are expected to drive market growth. Data Bridge Market Research analyzes that the Europe clinical trial imaging market will grow at a CAGR of 7.9% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customisable to 2019-2014)

Quantitative Units

Revenue in USD Million and Pricing in USD

Segments Covered

By Product and Services (Services and Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-ray, Ultrasound, Optical Coherence Tomography and Others), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Hematology and Others), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturers, Academic and Government Research Institutes and Others), Distributor (Direct Sales and Tender Sales)

Countries Covered

Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe

Market Players Covered

Navitas Life Sciences, Resonance Health Analytical Services, BioTelemetry, a Philips Company, IXICO plc, ICON plc, anagram 4 clinical trials, Quotient Sciences,WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group, and Invicro.LLC among others

Market Definition

Clinical trial is a process of developing new drugs. It is designed for potential treatment and its effects on humans. Before the commercialization of new drugs, extensive clinical testing is done to identify promising compounds, and safety tests are conducted to determine the possible risks.

In clinical trials, medical imaging plays a significant role in more accurate and effective results. Different imaging technologies may be used to elucidate and demonstrate the mechanistic actions of drugs. Clinical trial imaging is the process of clinical analysis and medical intervention by creating image representations of inner parts of the body. It has several different technologies which are used to view the human body to monitor, treat, and diagnose medical conditions.

In the coming future, important decisions related to clinical trial imaging on drug discovery will be made by individuals who not only understand the biopsy but can also use the clinical trial imaging tools and the knowledge they release to develop hypotheses and identify quality targets.

Europe Clinical Trial Imaging Market Dynamics

Drivers

  • Growth in the Pharmaceutical and Imaging Industries

Pharmaceutical and imaging industries conduct clinical trials to evaluate the safety and efficacy of drug development. They are among the fastest growing. Currently, more than 8% annual growth rate accounts for biopharmaceuticals, which is double the growth rate as compared to conventional pharma and growth is expected to continue at that rate for the foreseeable future. The development of a new drug is intensively used in pharmaceutical and imaging companies as they are one of the most research-oriented industries.

Many pharmaceutical companies are continuing to drive efficiencies in their processes of development to reduce costs associated with the process of new drug development. Many pharmaceutical companies are increasingly looking to consolidate the number of outsourcing providers with which they engage, with many strategic arrangements of partnership with a limited number of outsourcing providers. Some pharmaceutical companies have entered into a collaboration to develop new drugs. An increase in the number of collaborations between pharmaceutical companies has led to great opportunities in research.

Different types of collaboration and agreement increase the growth of pharmaceutical and imaging industries which act as a driver for market growth.

  • Rising R&D Expenditure

Imaging and pharma companies are continuously investing in R&D to offer innovative services for clinical trial imaging to customers and enhance their market presence. Medical imaging plays a dynamic role in clinical development. While the medical imaging industry is in a constant state of fluctuation due to implementation of new technologies in the market, the pharmaceutical and imaging industries continue to increase. This is attributed to enhanced investment in medical imaging companies along with mergers and acquisitions as well as the adoption of innovation in imaging technologies to support clinical trials for medical devices. Increasing R&D expenditure in pharmaceutical and biotechnological companies is fuelling market growth.

This has encouraged the development of new products and high research-oriented programs organized in biopharmaceutical industries and a high preference for the studies of human genome. Rising expenditure on R&D activities also develops new drugs and therapies to treat chronic diseases that boost market growth. This helps the pharmaceutical and biotechnological companies in the development of new technologies in the category of imaging clinical trials therefore, rising R&D expenditure is expected to drive the market growth.

Opportunities

  • Rise in Healthcare Expenditure

Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure.

For instance,

  • In October 2020, MedTech Europe Organization's report stated that the overall healthcare expenditure in Europe grew to reach approximately 10% of the GDP in 2020, which was 8.3% GDP in the year 2019, out of which 76.6% is spent on inpatient and outpatient care

Growing healthcare expenditure is also beneficial for further growth in the economic and healthcare sector, and it is primarily fruitful as it significantly affects the development of better and advanced medical products in the market. Therefore, the surge in healthcare expenditure is a greater opportunity for the market.

  • Strategic Initiatives by Market Players

The demand for clinical trial imaging is increasing in the market owing to the increased levels of R&D along with the growth of clinical trial imaging market aided by the desire for innovative medications. Thus, the top market players have implemented a new strategy by developing new products and collaborating with other market players to improve business operations and profitability.

For instance,

  • In February 2020, ICON plc acquired MedPass International, a European medical devices CRO, reimbursement and regulatory consultancy. This acquisition has reportedly helped in the expansion of the medical device and diagnostic research services of ICON in Europe.

These strategic initiatives by the market players, including acquisition, conferences and focused segment product launches, are helping them grow and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may act as an opportunity for market growth.

  • High-Risk Radiation Causing Diseases

In clinical medical imaging, radiation is absorbed by the body which can harm molecular structures inside the patient’s body. High doses of radiation can affect human cells including loss of hair, skin burns and increased incidence of cancer. The estimated risk of developing fatal cancer is one in 2000 after going through a radiation dose of 10 mSv in a CT scan.

For instance,

  • According to Radiological Society of America (RSNA), 1% to 2% of all cancers in the U.S. are caused by CT scans and the American Cancer Society identified CT scans and X-rays as one of the reasons for breast cancer, brain cancer and other cancers
  • According to the Center for Disease Control and Prevention, exposure to high levels of radiation results in acute radiation syndrome. The amount of radiation that a person's body absorbs is called the radiation dose.

The high-risk radiation that occurs, would decrease the usage and sale of clinical trial imaging devices, thereby affecting the credibility of manufacturers involved in this market. Therefore, the high-risk radiation-causing diseases are expected to restrain the market growth.

  • Strict Regulatory Policies

The healthcare industry is regulated by a structure of laws and rules & regulations that are extensive and complex.

For instance,

  • In April 2018, the U.S. FDA released updated Guidance for Clinical Trial Imaging Endpoint Process Standards for the industry which includes the quality of imaging data obtained in clinical trials
  • Biotechnology and pharmaceutical industries need to take first approval from the FDA for the process of drug development. They have to submit an Investigational New Drug (IND) application to the FDA before beginning clinical research.

COVID-19 Impact on the Europe Clinical Trial Imaging Market

Diagnostic imaging services have been time-consuming and complicated by the need for strict infection control and prevention practices developed to contain the risk of transmission and protect healthcare personnel. Hence, the decision to image suspected patients or COVID-19-positive patients is based on their impact on the improvement of patient status.

Countries in Europe with a lower GDP reduced cardiac imaging procedures in April 2020, to prevent their healthcare systems becoming overwhelmed. In addition to policies cancelling non-urgent investigations, other important factors may have driven the decline in performance of imaging procedures, such as patient’s inability or reluctance to seek healthcare advice during the COVID-19 pandemic. This includes factors such as fear, a desire to avoid potential infection, access to public transport, and other essential axillary services. This appeared to be part of a general pattern of reduced healthcare utility for non-COVID-19 conditions during the pandemic.

Recent Developments

  • In January 2022, Clario partnered with XingImaging, a radiopharmaceutical production and Positron Emission Tomography (PET) acquisition company, to deliver PET imaging clinical trials for testing novel therapeutics in China. The partnership offers to share the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China.
  • In November 2021, Clario was formed. ERT and Bioclinica, merged to form Clario. The formation of a new company resulted in distribution of clinical imaging software and services and rise in sales.

Europe Clinical Trial Imaging Market Scope

Europe clinical trial imaging market is segmented into five segments based on product and services, modality, application, end user, and distributor. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

  • Services
  • Software

Based on product and services, the market is segmented into services and software.

Modality

  • Computed Tomography
  • Magnetic Resonance Imaging
  • Echocardiography
  • Nuclear Medicine
  • Positron Emission Tomography
  • X-ray
  • Ultrasound
  • Optical Coherence Tomography
  • Others

Based on modality, the market is segmented into computed tomography, magnetic resonance imaging, echocardiography, nuclear medicine, positron emission tomography, X-ray, ultrasound, optical coherence tomography and others.

Application

  • Oncology
  •  Neurology
  •  Cardiology
  •  Endocrinology
  •  Dermatology
  •  Hematology
  •  Others

Based on application, the market is segmented into oncology, neurology, cardiology, endocrinology, dermatology, hematology and others.

End user

  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Medical Device Manufacturers
  • Academic and Government Research Institutes
  • Others

Based on end user, the market is segmented into contract research organizations, pharmaceutical & biotechnology companies, medical device manufacturers, academic and government research institutes and others.

Distributor

  • Direct Sales
  •  Tender Sales

Clinical Trial Imaging Market

Based on distributor, the market is segmented into direct sales and tender sales.

Europe Clinical Trial Imaging Market Regional Analysis/Insights

Europe clinical trial imaging market is analyzed, and market size insights and trends are provided by regions, product and services, modality, application, end user, and distributor as referenced above.

The countries covered in this market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe. Germany is expected to dominate the market since clinical imaging market in Germany is the single largest market in Europe, and proficient to accumulate innovative medical imaging technologies. At the same time, the high number of well-qualified users provides a powerful platform for the further development of medical imaging technologies.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Clinical Trial Imaging Market Share Analysis

The Europe clinical trial imaging market competitive landscape provides details on the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, the Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the Europe clinical trial imaging market.

Some of the major players operating in the market are Navitas Life Sciences, Resonance Health Analytical Services, BioTelemetry, a Philips Company, IXICO plc, ICON plc, anagram 4 clinical trials, Quotient Sciences,WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group, and Invicro.LLC among others.


SKU-
Why Choose Us


Frequently Asked Questions

The Europe Clinical Trial Imaging Market is anticipated to reach a CAGR of 7.9% outlook by 2029
The Europe Clinical Trial Imaging Market is segmented by Product and Services, Modality, Application, End User & Distributor
Europe Clinical Trial Imaging Market covers these countries namely Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe.
Germany is expected to dominate the market since the clinical imaging market in Germany is the single largest market in Europe, and is proficient to accumulate innovative medical imaging technologies.